Browse Studies — Arctuva

Phase 2

A Phase 2 Study of Atezolizumab With Selinexor in Alveolar Soft Part Sarcoma (AXIOM)

This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the…

Advanced Alveolar Soft Part SarcomaAdvanced Soft Tissue SarcomaMetastatic Alveolar Soft Part Sarcoma+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05333458

Phase 1

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usu…

Advanced Dedifferentiated LiposarcomaAdvanced LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06498648

Phase 1

A Seamless Phase 1/2 Open-label Study to Evaluate the Safety, Determine the Maximum Tolerated Dose of Administered Activity, and Evaluate the Efficacy of the Therapeutic Radiopharmaceutical [Ac 225]-RTX-2358 in the Treatment of Relapsed or Refractory Sarcoma

The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio …

Advanced Soft Tissue Sarcoma

Estimated

~$10 – $8,750

Ratio Therapeutics, Inc.NCT07156565

Phase 1

SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN for Previously Treated Advanced Soft Tissue Sarcoma (STS)

This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN given intravenously with defined doses of IPILIMUMAB and NIVOLUMAB ba…

Advanced Soft Tissue SarcomaMetastatic Soft Tissue Sarcoma

Estimated

~$10 – $6,250

Sarcoma Oncology Research Center, LLCNCT03138161